Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs)

Long-acting injectable antiretroviral therapy (LA ART) has been found to be non-inferior to daily oral ART in phase 3 clinical trials and is poised to soon enter routine clinical care. This treatment modality has the potential to address many barriers to daily oral ART adherence among people living...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2022-11, Vol.75 (Suppl 4), p.S549-S556
Main Authors: Kityo, Cissy, Cortes, Claudia P, Phanuphak, Nittaya, Grinsztejn, Beatriz, Venter, Francois
Format: Article
Language:English
Subjects:
Anti-HIV Agents - therapeutic use
Anti-Retroviral Agents - therapeutic use
Developing Countries
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Infections - prevention & control
Humans
Poverty
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long-acting injectable antiretroviral therapy (LA ART) has been found to be non-inferior to daily oral ART in phase 3 clinical trials and is poised to soon enter routine clinical care. This treatment modality has the potential to address many barriers to daily oral ART adherence among people living with human immunodeficiency virus (HIV) and for HIV Pre-Exposure prevention. Data from the Patient Reported Outcomes (PROs) showed high rates of satisfaction, acceptability, tolerability and preference for the LA regimen, compared with the daily oral treatment. Once LA ART is available, access and uptake will be limited because of current knowledge gaps in the use of these agents and multiple challenges many specific to low-income and middle-income countries, where the epidemic is most concentrated and HIV prevention and treatment options are limited. These gaps will lead to multiple systems-level and individual-level barriers to implementation. Anticipating and addressing these gaps and barriers will help fulfill the promise of these agents against the pandemic.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciac752